SKYLINEDX ANNOUNCES UPCOMING ORAL PRESENTATION AT THE 21ST INTERNATIONAL CONGRESS OF THE SOCIETY FOR MELANOMA RESEARCH
SKYLINEDX ANNOUNCES UPCOMING ORAL PRESENTATION AT THE 21ST INTERNATIONAL CONGRESS OF THE SOCIETY FOR MELANOMA RESEARCH
ROTTERDAM, Netherlands and SAN DIEGO, Oct. 8, 2024 /PRNewswire/ -- SkylineDx, an innovative diagnostics company specializing in the research and development of molecular diagnostics for oncology, inflammatory, and infectious diseases, announces that late-breaking data evaluating its Merlin test will be presented as part of the Plenary Session and a poster presentation at the upcoming Society for Melanoma Research (SMR) being held from October 10-13, 2024, in New Orleans, LA.
荷兰鹿特丹和美国圣地亚哥，2024年10月8日 /PRNewswire/ -- SkylineDx，一家专注于肿瘤学、炎症和传染病分子诊断研究与开发的创新诊断公司，宣布将在即将举行的美国新奥尔良举办的2024年10月10-13日举行的黑色素瘤研究学会（SMR）的全体大会和海报展示中发布评估其Merlin测试的最新数据。
|
The oral presentation will be part of Plenary Session 10: Late Breaking Clinical Abstracts | |
|
Oral |
"Prospective Multicenter Evaluation (MERLIN_001 Trial) of Clinicopathologic and Gene |
|
Expression Profile Test to Predict Sentinel Node Status in T1-T3 cNO Melanoma |
|
|
Date |
Sunday, October 13 |
|
Time |
10:45 AM CDT |
|
Presenter |
Vernon K. Sondak, MD, Department Chair, Cutaneous Oncology, Moffitt Cancer Center |
|
Poster Presentation Details | |
|
Poster |
CP-GEP Identifies T1a Melanoma Patients at Risk of Sentinel Lymph Node Metastasis |
|
Date |
Friday, October 11 |
|
Time |
1:00 – 2:00 PM CDT |
|
Presenter |
Alex Meves, MD, MBA, Dermatologist, Mayo Clinic |
|
口头报告将作为全体会议10：Late Breaking Clinical Abstracts的一部分。 | |
|
口头 |
“前瞻性多中心评估（MERLIN_001试验）临床病理学和基因表达谱测试，用于预测T1-T3 cNO黑色素瘤哨兵淋巴结状况 |
|
内 |
|
|
日期 |
星期日，十月十三日 |
|
Right Time |
上午十点四十五分 中部夏令时间 |
|
|
Vernon k. Sondak, MD, Cutaneous Oncology Department Chair, Moffitt Cancer Center |
|
海报展示详细信息 | |
|
海报 |
CP-GEP识别患有T1a黑色素瘤的患者，可能存在哨兵淋巴结转移的风险 |
|
日期 |
10月11日星期五 |
|
Right Time |
中部时间下午1点至下午2点 |
|
主持人 |
亚历克斯·梅维斯，MD，MBA，梅奥诊疗皮肤科专家 |
About CP-GEP (Merlin test)
CP-GEP is a non-invasive prediction model for cutaneous melanoma patients that combines clinicopathologic (CP) variables with gene expression profiling (GEP). This model is able to identify cutaneous melanoma patients at low-risk for nodal metastasis who may forgo the sentinel lymph node biopsy (SLNB) procedure. The CP-GEP model was developed by Mayo Clinic and SkylineDx BV and it has been clinically validated in multiple studies. More information (including references) may be obtained at www.falconprogram.com and merlinmelanomatest.com. The test has been launched in the United States and Europe as Merlin test. SkylineDx collaborates with diagnostic service providers globally to bring this test to market and increase patient access. In the United States, Tempus is commercializing Tempus Merlin test. Quest Diagnostics launched their own LDT version of the CP-GEP model in the United States under the brand name MelaNodal Predict.
关于CP-GEP（Merlin测试）
CP-GEP是一个非侵入性的预测模型，用于结合临床病理（CP）变量和基因表达谱（GEP）的黑色素瘤患者。该模型能够识别低风险淋巴结转移的黑色素瘤患者，可能可以避免前哨淋巴结活检（SLNB）程序。CP-GEP模型由Mayo Clinic和SkylineDx BV开发，已在多项研究中进行了临床验证。可在www.falconprogram.com和merlinmelanomatest.com获取更多信息（包括参考文献）。该测试已在美国和欧洲推出，称为梅林测试。SkylineDx与全球诊断服务提供商合作，将该测试引入市场并提高患者可及性。在美国，Tempus正在商业化Tempus Merlin测试。奎斯特诊疗在美国推出了他们自己的LDt版本的CP-GEP模型，品牌名为MelaNodal Predict。
About SkylineDx
SkylineDx is a biotechnology company focused on research & development of molecular diagnostics in oncology inflammatory, and infectious diseases. SkylineDx uses its expertise to bridge the gap between academically discovered gene expression signatures and commercially available diagnostic products with high clinical utility, assisting healthcare professionals in accurately determining the type or status of disease or predicting a patient's response to treatment. Based on test results, healthcare professionals can tailor the treatment approach to the individual patient. SkylineDx is headquartered in Rotterdam. the Netherlands, complemented by a U.S. base of operations and a CAP/CLIA certified laboratory in San Diego California, USA. To learn more about SkylineDx, please visit .
关于SkylineDx
SkylineDx是一家专注于肿瘤炎症和传染病分子诊断研究与开发的生物技术公司。SkylineDx利用其专业知识弥合了学术发现的基因表达特征与具有高临床效用的商业化诊断产品之间的差距，帮助医疗服务专业人员准确判断疾病类型或状态，预测患者对治疗的反应。基于测试结果，医疗服务专业人员可以针对个体患者定制治疗方案。SkylineDx总部位于荷兰鹿特丹，辅之以美国运营基地和位于美国加利福尼亚州圣迭戈的CAP/CLIA认证实验室。要了解更多关于SkylineDx，请访问。
SOURCE SkylineDx
来源：SkylineDx
